In vivo antibody library screening identifies PKM2-targeting M1 antibody with antitumor activity in melanoma.

Abstract

In this study, we introduce an innovative in vivo antibody screening method to identify antibodies that can inhibit melanoma cell growth and induce apoptosis. By using a lentiviral ScFv library, we developed a platform that allows for the direct suppression of melanoma cell proliferation within a living mouse model. Through this approach, we identified the M1 antibody, which targets PKM2, a key protein involved in tumor progression. The M1 antibody was found to significantly inhibit melanoma cell growth by disrupting the function of PKM2. Although PKM2 is widely recognized as an important factor in various cancers, no commercial therapeutic agents currently target this protein. Our findings indicate that the in vivo antibody screening method is a reliable and effective approach for isolating antibodies for melanoma therapy. Moreover, the M1 antibody shows great potential as a promising candidate for developing novel treatments for human melanoma.